FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an antibody or antigen-binding fragment thereof, specifically binding to IL-6, as well as to a pharmaceutical composition containing it. Also, disclosed is a method for treating an IL-6-associated disease or disorder using the above composition. Also, the invention relates to an isolated nucleic acid encoding the above antibody or antigen-binding fragment thereof, as well as to a vector and a host cell containing the above-mentioned nucleic acid.
EFFECT: invention makes it possible to effectively treat IL-6-associated diseases or disorders.
12 cl, 18 dwg, 26 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
| ANTI c-Met RECEPTOR PROTEIN ANTIBODIES | 2011 |
|
RU2608644C2 |
| ANTIBODIES TO CD70 | 2012 |
|
RU2604196C2 |
| PROTEIN BOUND WITH HUMAN GLYCOPROTEIN, COMPOSITION, PHARMACEUTICAL COMPOSITION, EXPRESSION VECTOR | 2016 |
|
RU2773819C2 |
| ISOLATED HUMANIZED PROTEIN BINDING TO HUMAN GLYCOPROTEIN VI, ISOLATED ANTIBODY BINDING TO HUMAN GLYCOPROTEIN VI | 2018 |
|
RU2778884C2 |
| HUMANIZATION OF RABBIT ANTIBODIES USING THE UNIVERSAL ANTIBODY FRAME | 2014 |
|
RU2652907C2 |
| HUMANIZING RABBIT ANTIBODIES USING A UNIVERSAL ANTIBODY FRAMEWORK | 2018 |
|
RU2696202C1 |
| HUMANISATION OF RABBIT ANTIBODIES USING UNIVERSAL ANTIBODY SCAFFOLD | 2009 |
|
RU2567006C2 |
| PROLACTIN RECEPTOR BINDING PROTEINS AND THEIR USE | 2013 |
|
RU2664463C2 |
| ANTIBODY THAT BINDS TO VEGF AND IL-1BETA, AND METHODS OF USE THEREOF | 2019 |
|
RU2816476C2 |
